{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115699","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.313370+00:00","generated_at":"2026-06-22T04:23:36.951445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia reports Q3 net loss $9.1M; secures key legal wins for YUTREPIA launch","bullets":["Net loss $9.1M ($0.14/share) vs $7.3M loss in Q3 2021; revenue flat at $3.2M.","Cash $98.3M as of Sep 30, 2022 vs $57.5M at Dec 31, 2021.","PTAB ruled '793 patent claims unpatentable; court invalidated '066 patent claims, remaining not infringed; '901 non-infringed.","Launch of YUTREPIA (treprostinil) likely 12-14 months after PTAB denies rehearing on '793 appeal.","R&D spend $4.5M flat; G&A up 38% to $6.7M on commercial prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115699","json":"https://secwatch.observer/filing/0001104659-22-115699.json","markdown":"https://secwatch.observer/filing/0001104659-22-115699.md","text":"https://secwatch.observer/filing/0001104659-22-115699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922115699/0001104659-22-115699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922115699/tm2229948d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:23:36.951445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c71c202314b5a99a79383d7f40d419a76c93bdca","claim":"Liquidia Corp reported third quarter ended September 30, 2022 results: revenue $3.2 million.","evidence_excerpt":"or dropping the device. Third Quarter 2022 Financial Results Cash totaled $98.3 million as of September 30, 2022, compared to $57.5 million as of December 31, 2021. Revenue was $3.2 million for the three months ended September 30, 2022, compared to $3.2 million for the three months ended September 30, 2021. Revenue related primarily to the Promotion Agreement.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922115699/0001104659-22-115699-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}